WHO/Lancet Modeling Study: Risk to South Sudan

A new modeling study from the World Health Organization published in The Lancet Infectious Diseases warns of imminent regional escalation.

• The model estimates a 69.3% probability that at least one Ebola case will reach South Sudan within the next 12 weeks .
• This finding has been reported consistently across WHO, The Lancet's press materials, and independent news coverage .

Reasons for the Explosive Trajectory

Public health authorities have identified several converging factors driving the outbreak's unprecedented speed.

• Delayed detection: The outbreak is believed to have begun spreading undetected as early as February 2026 in the town of Mongbwalu, Ituri Province — more than two months before it was officially declared on May 15 . This head start allowed the virus to establish in multiple locations before response efforts began.
• No approved vaccine or therapeutics: The Bundibugyo virus (Orthoebolavirus bundibugyoense) is a rare strain for which no licensed vaccine or specific treatment exists . The existing Zaire ebolavirus vaccine (Ervebo) may be partially effective in macaques, but the WHO has judged the evidence insufficient and has not recommended its use . This makes the outbreak fundamentally different from previous Ebola epidemics where ring vaccination could be deployed.
• Strained contact tracing: With cases growing exponentially and spread across remote, insecure areas, contact tracing capacity is overwhelmed. As of June 6, follow-up rates were just 43.2% in the hardest-hit Ituri Province .
• Attacks on treatment centers: The outbreak zone overlaps with active armed conflict and displacement. Insecurity and attacks on health facilities have repeatedly disrupted the response, hindering case management and isolation efforts .
• Poor isolation rates: CDC modeling shows that with only 20% of patients isolated — the current approximate level — there is a 65% probability the outbreak exceeds 20,000 cases within three months. If isolation could be raised to 70%, the risk of exceeding 10,000 cases drops to 5% .

International Response Efforts

A multi-agency emergency response is underway, constrained by the lack of medical countermeasures and the challenging security environment.

• PHEIC declared: The WHO Director-General declared a Public Health Emergency of International Concern (PHEIC) on May 17, 2026, citing urban spread, healthcare-worker infections, and the lack of approved countermeasures .
• Vaccine development fast-tracked: The Coalition for Epidemic Preparedness Innovations (CEPI) is urgently accelerating three investigational vaccines targeting the Bundibugyo strain . None are yet approved .
• Therapeutic trials starting: The WHO announced that trials of two separate potential treatments are expected to begin in the DRC in late June 2026 .
• WHO and partners on the ground: WHO is scaling up surveillance, contact tracing, clinical preparedness, and community engagement in both the DRC and Uganda . MSF (Médecins Sans Frontières) is scaling up its medical response in Ituri Province . The CDC is working through its country offices in the DRC and Uganda .
• UN response: The UN is supporting case management, infection prevention and control, and safe burial teams, with a focus on the high rates of infection among healthcare workers — what the WHO has characterized as "a disease you get when you care for someone" .

WHO/Lancet Modeling Study: Risk to South Sudan

A new modeling study from the World Health Organization published in The Lancet Infectious Diseases warns of imminent regional escalation.

• The model estimates a 69.3% probability that at least one Ebola case will reach South Sudan within the next 12 weeks .
• This finding has been reported consistently across WHO, The Lancet's press materials, and independent news coverage .

Reasons for the Explosive Trajectory

Public health authorities have identified several converging factors driving the outbreak's unprecedented speed.

• Delayed detection: The outbreak is believed to have begun spreading undetected as early as February 2026 in the town of Mongbwalu, Ituri Province — more than two months before it was officially declared on May 15 . This head start allowed the virus to establish in multiple locations before response efforts began.
• No approved vaccine or therapeutics: The Bundibugyo virus (Orthoebolavirus bundibugyoense) is a rare strain for which no licensed vaccine or specific treatment exists . The existing Zaire ebolavirus vaccine (Ervebo) may be partially effective in macaques, but the WHO has judged the evidence insufficient and has not recommended its use . This makes the outbreak fundamentally different from previous Ebola epidemics where ring vaccination could be deployed.
• Strained contact tracing: With cases growing exponentially and spread across remote, insecure areas, contact tracing capacity is overwhelmed. As of June 6, follow-up rates were just 43.2% in the hardest-hit Ituri Province .
• Attacks on treatment centers: The outbreak zone overlaps with active armed conflict and displacement. Insecurity and attacks on health facilities have repeatedly disrupted the response, hindering case management and isolation efforts .
• Poor isolation rates: CDC modeling shows that with only 20% of patients isolated — the current approximate level — there is a 65% probability the outbreak exceeds 20,000 cases within three months. If isolation could be raised to 70%, the risk of exceeding 10,000 cases drops to 5% .

International Response Efforts

A multi-agency emergency response is underway, constrained by the lack of medical countermeasures and the challenging security environment.

• PHEIC declared: The WHO Director-General declared a Public Health Emergency of International Concern (PHEIC) on May 17, 2026, citing urban spread, healthcare-worker infections, and the lack of approved countermeasures .
• Vaccine development fast-tracked: The Coalition for Epidemic Preparedness Innovations (CEPI) is urgently accelerating three investigational vaccines targeting the Bundibugyo strain . None are yet approved .
• Therapeutic trials starting: The WHO announced that trials of two separate potential treatments are expected to begin in the DRC in late June 2026 .
• WHO and partners on the ground: WHO is scaling up surveillance, contact tracing, clinical preparedness, and community engagement in both the DRC and Uganda . MSF (Médecins Sans Frontières) is scaling up its medical response in Ituri Province . The CDC is working through its country offices in the DRC and Uganda .
• UN response: The UN is supporting case management, infection prevention and control, and safe burial teams, with a focus on the high rates of infection among healthcare workers — what the WHO has characterized as "a disease you get when you care for someone" .